Search alternatives:
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
3421
HDX profile changes of βarr2 upon co-incubation with C7pp2.
Published 2025“…Differences smaller than 0.2 Da were not considered significant. The data underlying the graphs shown in the figure can be found in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003312#pbio.3003312.s009" target="_blank">S1 Data</a>.…”
-
3422
Table 1_Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center.docx
Published 2025“…TMA event-free status was reached in 15 (63%) patients. Significant improvements were observed in platelet count (63%), lactate dehydrogenase levels (76% within the first week), hemoglobin (60%), and estimated glomerular filtration rate (79%); while CH-50 levels decreased. …”
-
3423
-
3424
-
3425
Table 1_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.xlsx
Published 2025“…Transcriptomic analysis revealed that AT-1 significantly modulated the expression of S100A8 and S100A9. …”
-
3426
Image 2_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.tif
Published 2025“…Transcriptomic analysis revealed that AT-1 significantly modulated the expression of S100A8 and S100A9. …”
-
3427
Image 1_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.tif
Published 2025“…Transcriptomic analysis revealed that AT-1 significantly modulated the expression of S100A8 and S100A9. …”
-
3428
6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations
Published 2025“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
-
3429
6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations
Published 2025“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
-
3430
6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations
Published 2025“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
-
3431
6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations
Published 2025“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
-
3432
Data Sheet 1_Unveiling frailty: comprehensive and sex-specific characterization in prematurely aging PolgA mice.pdf
Published 2024“…We demonstrated that frailty became evident in PolgA mice around 40 weeks, validated through body weight loss, reduced walking speed, decreased physical activity, and weaker grip strength. …”
-
3433
Image 10_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg
Published 2025“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”
-
3434
Image 3_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg
Published 2025“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”
-
3435
Image 7_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.tif
Published 2025“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”
-
3436
Image 6_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg
Published 2025“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”
-
3437
Image 8_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg
Published 2025“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”
-
3438
Image 15_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg
Published 2025“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”
-
3439
Image 4_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.tif
Published 2025“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”
-
3440
Image 11_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg
Published 2025“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”